LegoChem Bio’s Phase II clinical trial of ‘Super Antibody’ designated for accelerated approval by FDA
LegoChem Biosciences(LegoChem Bio) officially announced that Delpazloid(LCB01-0371), a Phase II clinical trial pipeline, was designated as a medicine for the Fast Track process by the U.S. Food and Drug Administration(FDA).
Delpazolid, an antibody developed by LegoChem Bio on its own, has been o...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
